Sector News

Bristol-Myers Squibb announces leadership changes

December 17, 2019
Life sciences

Bristol-Myers Squibb Company announced today that John Elicker, Executive Vice President, Corporate Affairs and Investor Relations, will retire from the company March 31, 2020.

Kathryn Metcalfe, currently Chief Communications Officer of CVS Health, has been appointed Executive Vice President, Corporate Affairs, effective January 6, 2020. Tim Power has been appointed Vice President and Head of Investor Relations, effective March 31, 2020 upon Elicker’s retirement.

“On behalf of the company, I want to thank John for his leadership and the important contributions he’s made in his many years with Bristol-Myers Squibb,” said Giovanni Caforio, Chairman and Chief Executive officer, Bristol-Myers Squibb. “He has contributed to developing and executing our company strategy and has built a strong Corporate Affairs and Investor Relations team well positioned to continue to engage stakeholders around our company strategy, the performance of our business and our patient-focused mission.

“Kathryn is an accomplished and respected communications leader and I look forward to her leadership of the company’s communications at a time of growth and change for Bristol-Myers Squibb,” said Caforio. “She will play an important role on the leadership team as we engage with a broad range of stakeholders around our business, the promise of our pipeline and the exciting opportunities we are pursuing for patients.

“Tim is highly qualified to lead our Investor Relations team and I look forward to his leadership during an important time for the company,” he continued, “Tim has been instrumental in the company’s strategic positioning and communicating our financial, strategic, operational and business goals to investors and other key stakeholders.”

Metcalfe will report to Caforio and will sit on the Bristol-Myers Squibb leadership team. She will be responsible for leading the company’s strategic communications across stakeholder groups, including internal/external, global advocacy, state and federal government affairs and global policy.

Power will continue to report to Elicker until his retirement in March 2020, at which time Power will report to David Elkins, Executive Vice President and Chief Financial Officer. Power will lead all communications and engagement with the investment community.

Metcalfe joins Bristol-Myers Squibb from CVS Health, where she led communications following CVS’ acquisition of Aetna, where she was chief communications officer. At CVS Health, Metcalfe oversaw all strategic communications, internal and external, including reputation, and crisis management. Prior to CVS, Metcalfe held several senior Communications roles, including the Chief Communications Officer at Deloitte, and senior roles at Novartis and Pfizer as well as leadership roles at biotech and healthcare communications firms.

Source: Bristol-Myers Squibb

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach